Traws Pharma (TRAW) Q2 2024 earnings summary

Executive summary

• Completed a merger with Trawsfynydd Therapeutics in April 2024, expanding the clinical pipeline in virology and oncology and broadening the investor base to include OrbiMed and Torrey Pines.

• Advanced clinical pipeline with multiple candidates in influenza, COVID-19, and oncology, with key milestones expected in late 2024 and 2025.

• Completed a $14 million private placement concurrent with the merger, extending the cash runway through year-end 2024.

• Net loss for the six months ended June 30, 2024, was $128.1 million, primarily due to a $117.5 million non-cash in-process R&D charge from the acquisition.

• Cash and cash equivalents were $16.9 million as of June 30, 2024, with substantial doubt about the ability to continue as a going concern into the next year.

Financial highlights

• Net loss for Q2 2024 was $123.1 million ($4.87 per share), driven by a $117.5 million non-cash R&D charge.

• Cash, cash equivalents, and short-term investments totaled $16.9 million as of June 30, 2024, down from $20.8 million at year-end 2023.

• Revenue was $57,000 for Q2 2024 and $113,000 for the six months ended June 30, 2024, unchanged from the prior year.

• R&D expenses rose to $4.0 million in Q2 2024 from $2.5 million in Q2 2023, reflecting increased clinical activity and transaction-related costs.

• G&A expenses were $2.0 million in Q2 2024, slightly down from $2.2 million in Q2 2023.

Outlook and guidance

• Cash is expected to fund ongoing clinical trials and operations through year-end 2024, but additional financing may be required.

• Anticipates announcing top-line phase I results for influenza and COVID-19 candidates in Q4 2024, with phase II studies to begin in late 2024 or early 2025.

• Oncology programs to release phase I/II data and initiate investigator-sponsored trials in multiple myeloma and breast cancer in the second half of 2024.

• Management is exploring equity, strategic alliances, and other funding sources to extend the cash runway.

• The company may need to scale back operations if additional financing is not secured.